Cellular actions of opioids and other analgesics: Implications for synergism in pain relief

Clinical and Experimental Pharmacology and Physiology

Volumn 27, Issue 7, 2000, Pages 520-523

  Christie, MacDonald J ^b   Connor, Mark ^a,c   Vaughan, Christopher W ^a,c   Ingram, Susan L ^a,c   Bagley, Elena E ^a,c  

^a University of Sydney   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

5 lipoxygenase; Arachidonic acid; Non steroidal anti inflammatory drug; Opioid; Pain

Indexed keywords

ANALGESIC AGENT; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; MU OPIATE RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PHOSPHOLIPASE A2 INHIBITOR; POTASSIUM CHANNEL;

ANALGESIA; CENTRAL NERVOUS SYSTEM; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; GABAERGIC SYSTEM; RECEPTOR INTRINSIC ACTIVITY;

ANALGESICS; ANALGESICS, OPIOID; ANIMALS; DRUG SYNERGISM; HUMANS; NEURONS; PAIN;

EID: 0034047690     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.2000.03291.x     Document Type: Conference Paper

References (31)

1. 1. Dahl JB, Kehlet H. Non-sleroidal anti-inflammatory drugs: Rationale for use in severe postoperative pain. Br. J. Anaesth. 1991; 66: 703-12.
2. 2. Malmberg AB, Yaksh TL. Pharmacology of the spinal action of ketorolac, morphine, ST-91, U50488H and L-PIA on the formalin test and an isobolographic analysis of the NSAID interaction. Anesthesiology 1993; 79: 270-81.
3. 3. Maves TJ, Pechman PS, Meller ST, Gebhart GF. Ketorolac potentiates morphine antinociception during visceral nociception in the rat. Anesthesiology 1994; 80: 1094-101.
4. 4. Souter AJ, Fredman B, White PF. Controversies in the perioperative use of nonsteroidal antiinflammatory drugs. Anesth. Analg. 1994; 79: 1178-90.
5. 5. McCormack K. Non-steroidal anti-inflammatory drugs and spinal nociceptive processing. Pain 1994; 59: 9-43.
6. 6. Vaughan CW, Ingram SL, Connor M, Christie MJ. How opioids inhibit GABAergic neurotransmission. Nature 1997; 390: 611-14.
7. 7. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol. 1971; 231: 232-5.
8. 8. Hong Y, Abbott FV. Peripheral opioid modulation of pain and inflammation in the formalin test. Eur. J. Pharmacol. 1995; 277: 21-8.
9. 9. Levine JD, Taiwo YO. Involvement of the mu-opiate receptorin peripheral analgesia. Neuroscience 1989; 32: 571-5.
10. h, via adenylyl cyclase. Neuron 1994; 13: 179-86.
11. h) by cyclic nucleotides in guinea-pig primary afferent neurons. J. Physiol. 1996; 492: 97-106.
12. + current in rat sensory neurons in vitro. Neurosci. Lett. 1996; 212: 83-6.
13. 13. Bley KR, Hunter JC, Eglen RM, Smith JAM. The role of IP prostanoid receptors in inflammatory pain. Trends Pharmacol. Sci. 1998; 19: 141-4.
14. 2 binding sites in rat brain using quantitative autoradiography. Brain Res. 1992; 581: 292-8.
15. 15. Bjorkman RL, Hedner T, Hallman KM, Hedner J. Localization of the central antinociceptive effects of diclofenac in the rat. Brain Res. 1992; 590: 66-73.
16. 16. Tortorici V, Vasquez E, Vanegas H. Naloxone partial reversal of the antinociception produced by dipyrone microinjected into the periaqueductal gray of rats. Possible involvement of medullary off-and on-cells. Brain Res. 1996; 725: 106-10.
17. 17. Basbaum AI, Fields HL. Endogenous pain control systems: Brainstem spinal pathways and endorphin circuitry. Annu. Rev. Neurosci. 1984; 7: 309-38.
18. 18. Osborne PB, Vaughan CW, Wilson HI, Christie MJ. Opioid inhibition of rat periaqueductal gray neurones with identified projections to the rostral ventromedial medulla in vitro. J. Physiol. 1996; 490: 383-9.
19. 19. Vaughan CW. Enhancement of opioid inhibition of GABAergic synaptic transmission by cyclooxygenase inhibitors in rat periaqueductal grey neurons. Br. J. Pharmacol. 1998; 123: 1479-81.
20. 20. Vaughan CW, Christie MJ. Presynaptic inhibitory action of opioids on synaptic transmission in the rat periaqueductal grey in vitro. J. Physiol. 1997; 498: 463-72.
21. 2+ channel currents of acutely dissociated rat periaqueductal grey neurons. J. Physiol. 1998; 509: 47-58.
22. 22. Breder CD, Dewitt D, Kraig RP. Characterization of inducible cyclooxygenase in rat brain. J. Comp. Neurol. 1995; 355: 296-315.
23. 23. Piomelli D, Volterra A, Dale N et al. Lipoxygenase metabolites of arachidonic acid as second messengers for presynaptic inhibition of Aplysia sensory cells. Nature 1987; 328: 38-43.
24. 24. Bagley EE, Vaughan CW, Christie MJ. Inhibition by adenosine receptor agonists of synaptic transmission in rat periaqueductal grey neurons. J. Physiol. 1999; 516: 219-25.
25. 25. Simmons ML, Chavkin C. κ-Opioid receptor activation of a dendrotoxin-sensitive potassium channel mediates presynaptic inhibition of mossy fiber neurotransmitter release. Mol. Pharmacol. 1996; 50: 80-5.
26. 26. Levy RA, Proudfit HK. Analgesia produced by microinjection of baclofen and morphine at brainstem sites. Eur. J. Pharmacol. 1979; 57: 43-55.
27. 27. Vaughan CW, Connor MA, Bagley EE, Christie MJ. Actions of cannabinoids on membrane properties and synaptic transmission in periaqueductal grey neurons in vitro. Mol. Pharmacol. 2000; 57: 288-95.
28. 1 receptor ligand nociceptin on the membrane properties of rat periaqueductal grey neurons in vitro. J. Neurosci. 1997; 17: 996-1003.
29. 29. Lichtman AH, Cook SA, Martin BR. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: Evidence supporting periaqueductal grey involvement. J. Pharmacol. Exp. Ther. 1996; 276: 585-93.
30. 30. Welch SP, Thomas C, Patrick GS. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: Possible mechanisms for interaction with morphine. J. Pharmacol. Exp. Ther. 1995; 272: 310-21.
31. 31. Moren J, Francois T, Blanloeil Y, Pinaud M. The effects of a nonsteroidal antiinflammatory drug (ketoprofen) on morphine respiratory depression: A double-blind, randomized study in volunteers. Anesth. Analg. 1997; 85: 400-5.